Combining pembrolizumab with chemotherapy for advanced esophageal cancer before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of pembrolizumab in combination with albumin paclitaxel and carboplatin as a neoadjuvant therapy for patients with resectable locally advanced esophageal squamous cell carcinoma. Participants will receive two courses of this combination treatment before undergoing surgery, followed by continued pembrolizumab immunotherapy post-surgery. The study aims to evaluate the primary endpoint of pathological complete response (pCR) and major pathological response (MPR) to assess the treatment's efficacy and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Baseline stage resectable cII/III esophageal squamous cell carcinoma (8th UICC TNM stage);
2. Failure to receive anti-tumor treatment for esophageal squamous cell carcinoma;
3. Age range from 18 to 75 years old;
4. There are no surgical contraindications in the preoperative evaluation of various organ functions;
5. The following laboratory tests confirm that the bone marrow, liver and kidney functions meet the requirements for participating in the study: hemoglobin ≥ 9.0g/L; White blood cell count 4.0-10 × 109/L; Neutrophil absolute value (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100 × 109/L; Total bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST ≤ 2.5 times the upper limit of normal values; The international standardized ratio of prothrombin time is ≤ 1.5 times the upper limit of normal values, and some prothrombin time is within the normal range; Creatinine ≤ 1.5 times the upper limit of normal value;
6. Patients who have not undergone chemotherapy, radiation therapy, or hormone therapy for malignant tumors, have no history of other malignant tumors, and do not include prostate cancer patients who have received hormone therapy and have obtained DFS for more than 5 years;
7. Expected to achieve R0 resection;
8. Physical state ECOG 0-1;
9. The subjects must understand and sign the informed consent form

Exclusion Criteria:

1. Individuals who have received previous treatment for esophageal cancer (surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.);
2. Not suitable for surgery or with surgical contraindications;
3. Have a history of other anti PD-L1/PD-1 treatments;
4. Individuals with immunodeficiency or long-term systemic steroid therapy, or those who have received any immunosuppressive therapy within 7 days prior to receiving the study drug;
5. Individuals with active autoimmune diseases requiring systemic treatment within 2 years;
6. Patients with poor control of heart disease
7. Pregnant or lactating female patients;
8. For patients with drug allergies in the protocol.

Exit criteria：

Withdrawal cases refer to subjects who have stopped continuing treatment in clinical research due to various reasons. Subjects who experience the following situations will withdraw from the investigational treatment:

1. The main indicators are missing, and more than half of the items that can be filled in CRF are missing;
2. The surgical procedure violates the plan;
3. Cases that are excluded due to adverse reactions are not evaluated for efficacy, but side effects should be included in the statistics;
4. According to the researcher's opinion, continuing to participate in the study will be harmful to their health;
5. Patients who fail to undergo non-surgical treatment due to various reasons, including malignant tumor progression, underlying disease progression, patient or their trustee requesting withdrawal, will be reported together;
6. Missing subjects. All subjects who withdrew from the study should record their reasons for withdrawal in the CRF and their medical records. According to the ITT principle, all withdrawn cases should undergo survival analysis and toxicity evaluation for the corresponding group.

Where it's running

• Shanghai General Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiang Fan, MD
• Email: fan_jiang@tongji.edu.cn
• Phone: 15901013210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• Combining TIL Therapy and Pembrolizumab for Advanced Stomach and Esophageal Cancer

  This study is testing a new treatment that combines a type of immune therapy using patients' own tumor cells with a drug called Pembrolizumab to see if it helps people with advanced stomach and esophageal cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06532799

• Combination treatment for advanced esophageal cancer

  This study is testing a new combination of treatments for patients with advanced esophageal cancer to see if it is safe and effective for those who haven't had treatment before.

  Recruiting at 46 sites Phase 1/2 Merck Sharp & Dohme LLC · Tucson, Arizona and 49 other locations · NCT06469944

• Combining pembrolizumab, trastuzumab, and chemotherapy for HER2+ esophagogastric cancer

  This study is testing if adding pembrolizumab and trastuzumab to standard chemotherapy can help people with resectable HER2+ esophagogastric cancer do better in their treatment.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 9 other locations · NCT06123338

• Treatment of solid tumors or lymphoma with VMD-928

  This study is testing a new oral medication called VMD-928 to see if it can help adults with advanced solid tumors or lymphoma that haven't improved with standard treatments.

  Recruiting at 13 sites Phase 1/2 VM Oncology, LLC · Santa Rosa, California and 12 other locations · NCT03556228

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.